KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

GoodRx Holdings (GDRX) Interest Expenses (2019 - 2026)

GoodRx Holdings' Interest Expenses history spans 7 years, with the latest figure at $10.4 million for Q4 2025.

  • On a quarterly basis, Interest Expenses fell 8.41% to $10.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was $42.6 million, a 19.49% decrease, with the full-year FY2025 number at $42.6 million, down 19.49% from a year prior.
  • Interest Expenses hit $10.4 million in Q4 2025 for GoodRx Holdings, down from $10.8 million in the prior quarter.
  • Over the last five years, Interest Expenses for GDRX hit a ceiling of $14.8 million in Q4 2023 and a floor of $5.9 million in Q1 2022.
  • Historically, Interest Expenses has averaged $10.5 million across 5 years, with a median of $10.8 million in 2025.
  • Biggest five-year swings in Interest Expenses: crashed 31.64% in 2021 and later skyrocketed 123.77% in 2023.
  • Tracing GDRX's Interest Expenses over 5 years: stood at $5.9 million in 2021, then soared by 102.05% to $11.9 million in 2022, then rose by 24.26% to $14.8 million in 2023, then fell by 23.37% to $11.4 million in 2024, then dropped by 8.41% to $10.4 million in 2025.
  • Business Quant data shows Interest Expenses for GDRX at $10.4 million in Q4 2025, $10.8 million in Q3 2025, and $10.7 million in Q2 2025.